


12357
BL



**SUPERIOR COURT OF CALIFORNIA
COUNTY OF SAN FRANCISCO**

Document Scanning Lead Sheet

Mar-12-2019 12:22 pm

Case Number: CGC-19-574459

Filing Date: Mar-12-2019 12:19

Filed by: BOWMAN LIU

Image: 06722138

COMPLAINT

CHRISTINA LABAJO ET AL VS. GENERAL NUTRITION CORPORATION ET AL

001C06722138

Instructions:

Please place this sheet on top of the document to be scanned.

SUMMONS (CITACION JUDICIAL)

NOTICE TO DEFENDANT: (AVISO AL DEMANDADO):

GENERAL NUTRITION CORPORATION and
DOES 1-100

YOU ARE BEING SUED BY PLAINTIFF: (LO ESTÁ DEMANDANDO EL DEMANDANTE):

CHRISTINA LABAJO, HOWARD CLARK AND BERRY SAIZON

FOR COURT USE ONLY
(SOLO PARA USO DE LA CORTE)

NOTICE! You have been sued. The court may decide against you without your being heard unless you respond within 30 days. Read the information below.

You have 30 CALENDAR DAYS after this summons and legal papers are served on you to file a written response at this court and have a copy served on the plaintiff. A letter or phone call will not protect you. Your written response must be in proper legal form if you want the court to hear your case. There may be a court form that you can use for your response. You can find these court forms and more information at the California Courts Online Self-Help Center (www.courtinfo.ca.gov/selfhelp), your county law library, or the courthouse nearest you. If you cannot pay the filing fee, ask the court clerk for a fee waiver form. If you do not file your response on time, you may lose the case by default, and your wages, money, and property may be taken without further warning from the court.

There are other legal requirements. You may want to call an attorney right away. If you do not know an attorney, you may want to call an attorney referral service. If you cannot afford an attorney, you may be eligible for free legal services from a nonprofit legal services program. You can locate these nonprofit groups at the California Legal Services Web site (www.lawhelpcalifornia.org), the California Courts Online Self-Help Center (www.courtinfo.ca.gov/selfhelp), or by contacting your local court or county bar association. **NOTE:** The court has a statutory lien for waived fees and costs on any settlement or arbitration award of \$10,000 or more in a civil case. The court's lien must be paid before the court will dismiss the case.

¡AVISO! Lo han demandado. Si no responde dentro de 30 días, la corte puede decidir en su contra sin escuchar su versión. Lea la información a continuación.

Tiene 30 DÍAS DE CALENDARIO después de que le entreguen esta citación y papeles legales para presentar una respuesta por escrito en esta corte y hacer que se entregue una copia al demandante. Una carta o una llamada telefónica no lo protegen. Su respuesta por escrito tiene que estar en formato legal correcto si desea que procesen su caso en la corte. Es posible que haya un formulario que usted pueda usar para su respuesta. Puede encontrar estos formularios de la corte y más información en el Centro de Ayuda de las Cortes de California (www.sucorte.ca.gov), en la biblioteca de leyes de su condado o en la corte que le quede más cerca. Si no puede pagar la cuota de presentación, pida al secretario de la corte que le dé un formulario de exención de pago de cuotas. Si no presenta su respuesta a tiempo, puede perder el caso por incumplimiento y la corte le podrá quitar su sueldo, dinero y bienes sin más advertencia.

Hay otros requisitos legales. Es recomendable que llame a un abogado inmediatamente. Si no conoce a un abogado, puede llamar a un servicio de remisión a abogados. Si no puede pagar a un abogado, es posible que cumpla con los requisitos para obtener servicios legales gratuitos de un programa de servicios legales sin fines de lucro. Puede encontrar estos grupos sin fines de lucro en el sitio web de California Legal Services, (www.lawhelpcalifornia.org), en el Centro de Ayuda de las Cortes de California, (www.sucorte.ca.gov) o poniéndose en contacto con la corte o el colegio de abogados locales. **AVISO:** Por ley, la corte tiene derecho a reclamar las cuotas y los costos exentos por imponer un gravamen sobre cualquier recuperación de \$10,000 ó más de valor recibida mediante un acuerdo o una concesión de arbitraje en un caso de derecho civil. Tiene que pagar el gravamen de la corte antes de que la corte pueda desechar el caso.

The name and address of the court is:

(El nombre y dirección de la corte es): San Francisco Superior Court
400 McAllister Street
San Francisco, CA 94111

CASE NUMBER:
(Número del Caso):

005-19-574459

The name, address, and telephone number of plaintiff's attorney, or plaintiff without an attorney, is:

(El nombre, la dirección y el número de teléfono del abogado del demandante, o del demandante que no tiene abogado, es):

Wyatt A. Lison, 429 Fourth Avenue, Law & Finance Bldg., Ste. 1300, Pittsburgh, PA 15219 (412) 281-8400

DATE:

MAR 12 2019

DEPUTY CLERK

Clerk, by

(Secretario)

, Deputy

(Adjunto)

(For proof of service of this summons, use Proof of Service of Summons (form POS-010).)

(Para prueba de entrega de esta citación use el formulario Proof of Service of Summons, (POS-010).)

BOWMAN

[SEAL]



NOTICE TO THE PERSON SERVED: You are served

1. ☐ as an individual defendant.
2. ☐ as the person sued under the fictitious name of (specify):
3. ☐ on behalf of (specify):

under: <input type="checkbox"/> CCP 416.10 (corporation)	<input type="checkbox"/> CCP 416.60 (minor)
<input type="checkbox"/> CCP 416.20 (defunct corporation)	<input type="checkbox"/> CCP 416.70 (conservatee)
<input type="checkbox"/> CCP 416.40 (association or partnership)	<input type="checkbox"/> CCP 416.90 (authorized person)
<input type="checkbox"/> other (specify):	
4. ☐ by personal delivery on (date):

Wyatt A. Lison (SBN – 316775)
wlison@fdpklaw.com
**FEINSTEIN DOYLE PAYNE
& KRAVEC, LLC**
429 Fourth Avenue, Suite 1300
Pittsburgh, PA 15219
Tel.: (412) 281-8400
Fax: (412) 281-1007

John Peter Zavez (*pro hac vice* to be filed)
jzavez@akzlaw.com
ADKINS, KELSTON & ZAVEZ, P.C.
90 Canal Street, Suite 120
Boston, MA 02114
Telephone: (617) 367-1040
Facsimile: (617) 742-8280

ATTORNEYS FOR PLAINTIFFS

**SUPERIOR COURT OF THE STATE OF CALIFORNIA
FOR THE COUNTY OF SAN FRANCISCO**

**CHRISTINA LABAJO, HOWARD CLARK,
and BERRY SAIZON**

Plaintiffs,

v.

**GENERAL NUTRITION CORPORATION
and DOES 1-100**

Defendants.

CASE NO.:

CGC - 19-574459

COMPLAINT FOR:

- (1) Violation of the Unfair Competition
Law, Cal. Bus. & Prof. Code §§
17200, *et seq.*
- (2) Violation of the Consumers Legal
Remedies Act, California Civil Code
§§ 1750, *et seq.*

FILED
Superior Court of California
County of San Francisco

MAR 12 2019

CLERK OF THE COURT

BY: *[Signature]* Deputy Clerk

COWMAN LU

FILED VIA FAX

1 Plaintiffs Christina Labajo, Howard Clark and Berry Saizon (collectively Plaintiffs), by and
2 through their attorneys, bring this action against Defendant General Nutrition Corporation ("GNC"),
3 and allege as follows based upon their personal experiences as to their own acts and status, and based
4 upon the investigation of their counsel, and information and belief as to all other matters:

5 **NATURE OF THE CASE**

6 1. This is an action primarily seeking declaratory and injunctive relief to restrain GNC
7 from selling dietary supplements mislabeled with unlawful disease claims in California, commonly
8 referred to as "Health Fraud" by federal food and drug regulators (hereinafter the "Products"¹).

9 2. As explained herein, the U.S. Food and Drug Administration ("FDA"), after a
10 deliberative process and in its final rule in implementing regulations defining the use of
11 structure/function claims on dietary supplements, determined that supplements cannot expressly or
12 impliedly claim to lower cholesterol because it implies treatment for coronary heart disease, rendering
13 the claim misleading and making the product classified as a drug subject to pre-approval based on
14 safety and efficacy. Despite the misleading nature of cholesterol claims on supplements, GNC labels
15 five supplements as being able to maintain and/or support normal or healthy cholesterol levels, without
16 clarifying that they cannot lower cholesterol by stating that they may only maintain cholesterol levels
17 that are already within a normal range, which FDA has said is necessary to avoid implying treatment
18 for hypercholesterolemia and coronary heart disease.

19 3. Similarly, after the same deliberative process and within the same final rule, FDA
20 determined that dietary supplements cannot expressly or impliedly claim to build, strengthen or
21 maintain bones in menopausal women because it misleadingly implies treatment for osteoporosis, a
22 condition typically experienced by women who have gone through menopause and makes the product
23 a drug subject to pre-approval based on safety and efficacy. Yet, GNC labels three supplements
24 targeted towards menopausal women as able to help build, support, and/or maintain bones.

25 ¹ The term Products used herein refers to GNC Healthy Cholesterol Formula (Exhibit 1), GNC
26 Policosanol (Exhibit 2), GNC Ultra 35 Probiotic Complex with Cholesterol Support (Exhibit 3), GNC
27 Probiotic Solutions Adult 50 Plus (Exhibit 4), GNC Women's Ultra Mega 50 Plus Vitapak (Exhibit
28 5), GNC Women's Ultra Mega Menopause Vitapak (Exhibit 6), and GNC Women's Ultra Mega 50
Plus (Exhibit 7).

1 4. The labeling of GNC's Products as being able to cure, treat, mitigate or prevent
2 hypercholesterolemia, coronary heart disease, and/or osteoporosis in menopausal women is both
3 unlawful, it is also a "Health Fraud" because GNC's Products have not been approved as safe and
4 effective for these intended purposes. Under the U.S. Food, Drug and Cosmetic Act ("FDCA") and
5 identical provisions in California's Sherman Food, Drug, and Cosmetic Law, Cal. Health & Safety
6 Code §§ 109875, *et seq* ("Sherman Law"), products that claim to cure, treat, mitigate or prevent
7 diseases or conditions like hypercholesterolemia, coronary heart disease and osteoporosis are defined
8 as drugs. Sherman Law § 109925 and FDCA § 201(g)(1). Drugs may not be manufactured, labeled
9 or sold without prior approval of FDA. 21 U.S.C. §§ 331(d) and 355(a); Sherman Law § 111550. In
10 violation of these laws, GNC's Products shown in Exhibits 1-7 are labeled to cure, treat, mitigate or
11 prevent hypercholesterolemia (i.e., high cholesterol), coronary heart disease, and/or osteoporosis
12 without prior FDA approval. This identical conduct serves as the sole factual basis of each state law
13 cause of action brought by this Complaint, and Plaintiffs do not seek to enforce any of the state law
14 claims raised herein to impose any standard of conduct that exceeds that which would violate the
15 FDCA and regulations adopted pursuant thereto. Thus, Plaintiffs' state law claims are not preempted
16 by the FDCA because Plaintiffs' claims for state law violations seek to enforce the same standard of
17 conduct required by federal law and Plaintiffs' state law claims are based upon GNC's breach of that
18 standard of conduct. For any of Plaintiffs' state law causes of action, the allegations supporting those
19 causes of action and any forms of relief sought for those state law causes of action, Plaintiffs expressly
20 disclaim any attempt to hold GNC to a higher standard of conduct than what is required under federal
21 law, and do not seek any form of relief based on conduct exceeding that which is required under federal
22 law. All state law causes of action asserted in this Complaint, the allegations supporting those state
23 law causes of action asserted herein and any forms of relief sought for those state law causes of action
24 asserted herein shall be read consistent with the limitations set forth in this paragraph.

25 5. Accordingly, Plaintiffs bring this action pursuant to Bus. & Prof. Code § 17203 and
26 Cal. Civ. Code § 1780(a)(2) to enjoin GNC from continuing to sell dietary supplements California
27 labeled with the unlawful disease or treatment claims alleged throughout this Complaint, and to
28 recover the amounts Plaintiffs paid for the GNC products they purchased.

1

2

10

11

1 willing to pay the price she did for the GNC product, she would have purchased a lesser quantity of
2 the GNC product, she would have purchased another dietary supplement product, or she would have
3 purchased a similar dietary supplement that was less expensive.

4 8. Plaintiff Howard Clark is a citizen of the State of California and a resident of San
5 Francisco County, California. Between July 2016 and February 2017, Mr. Clark purchased at least
6 the following GNC dietary supplements: GNC Healthy Cholesterol Formula, GNC Probiotic
7 Solutions Adults 50 Plus and GNC Ultra 35 Probiotic Complex with Cholesterol Support. Mr. Clark
8 purchased these products from GNC stores in San Francisco County, California and paid between
9 \$9.00 and \$40.00 for each of the products purchased. The Healthy Cholesterol Formula product Mr.
10 Clark purchased was prominently labeled as able to “support[] normal, healthy cholesterol &
11 triglyceride levels with clinically studied black tea extract.” The Probiotic Solutions Adults 50 Plus
12 product that Mr. Clark purchased was prominently labeled as “support[ing] healthy cholesterol &
13 vitamin D levels.” The Ultra 35 Probiotic Complex that Mr. Clark purchased was prominently labeled
14 as “[c]linically studied support for healthy cholesterol levels,” which is reinforced on the back label
15 which states the product contains “[s]pecialized probiotic strains for cholesterol support.” Mr. Clark
16 purchased GNC’s products relying, in part, on the above-identified labeling statements made on the
17 products’ labels believing they were lawfully marketed to help lower his cholesterol level, and thereby
18 help cure, treat, prevent or mitigate coronary heart disease, and more effective than other similar
19 dietary supplements sold by other manufacturers that were not labeled to help lower cholesterol level.
20 Had the GNC products that Mr. Clark purchased not stated or implied that they could help lower his
21 cholesterol level, this would have affected Mr. Clark’s purchasing decisions in that he either would
22 not have purchased the GNC products, he would not have been willing to pay the price he did for the
23 GNC products, he would have purchased a lesser quantity of the GNC product, he would have
24 purchased other dietary supplement products, or he would have purchased a similar dietary supplement
25 that was less expensive.

26 9. Plaintiff Berry Saizon is a citizen of the State of California and a resident of Los
27 Angeles County, California. Between October 2017 and February 2018, Mr. Saizon purchased at least
28 the following GNC dietary supplements: GNC Healthy Cholesterol Formula and GNC Probiotic

1 Solutions Adults 50 Plus. Mr. Saizon purchased these products from GNC stores in Los Angeles
2 County, California and paid around \$20.00 for the GNC Healthy Cholesterol Formula and around
3 \$40.00 for the GNC Probiotic Solutions Adults 50 Plus. The GNC Healthy Cholesterol Formula Mr.
4 Saizon purchased was prominently labeled as able to “support[] normal, healthy cholesterol &
5 triglyceride levels with clinically studied black tea extract.” The GNC Probiotic Solutions Adults 50
6 Plus that Mr. Saizon product was prominently labeled as “support[ing] healthy cholesterol & vitamin
7 D levels.” Mr. Saizon purchased GNC’s products relying, in part, on the above-identified labeling
8 statements made on the products’ labels believing they were lawfully marketed to help lower his
9 cholesterol level, and thereby help cure, treat, prevent or mitigate coronary heart disease, and more
10 effective than other similar dietary supplements sold by other manufacturers that were not labeled to
11 help lower cholesterol level. Had the GNC products that Mr. Saizon purchased not stated or implied
12 that they could help lower his cholesterol level, this would have affected Mr. Saizon’s purchasing
13 decisions in that he either would not have purchased the GNC products, he would not have been willing
14 to pay the price he did for the GNC products, he would have purchased a lesser quantity of the GNC
15 product, he would have purchased other dietary supplement products, or he would have purchased a
16 similar dietary supplement that was less expensive.

17 10. General Nutrition Corporation is a corporation organized under the law of the
18 Commonwealth of Pennsylvania. General Nutrition Corporation is the successor-by-merger of GNC
19 Franchising, LLC, a Pennsylvania corporation. General Nutrition Corporation’s principal place of
20 business is located at 300 Sixth Street, Pittsburgh, Pennsylvania 15222. General Nutrition Corporation
21 is a health and wellness company that sells various nutritional supplements and vitamins throughout
22 the country. General Nutrition Corporation is identified as the “Distributor” of the Products at issue
23 in this lawsuit. *See* Exhibits 1-7.

24 11. Defendants Does 1 to 100, inclusive, are sued under fictitious names pursuant to Code
25 of Civil Procedure section 474. Plaintiffs allege, based on information and belief, that each of the
26 defendants sued under fictitious names is in some manner responsible for the wrongs and damages
27 alleged below, in so acting was functioning as the agent, servant, partner, and employee of General
28 Nutrition Corporation, and in taking the actions mentioned below was acting within the course and

1 scope of his or her authority as such agent, servant, partner, and employee, with the permission and
2 consent of General Nutrition Corporation or other Doe co-defendants.

3 **FACTUAL ALLEGATIONS**

4 **BACKGROUND OF DRUG AND DIETARY SUPPLEMENT LAWS AND REGULATIONS**

5 12. The purpose of food and drug laws, including the FDCA, FDA regulations and the
6 Sherman Law, is consumer protection. These laws and regulations were enacted, in part, to prohibit
7 the sale of misbranded food and drugs.

8 13. Amongst other things, the FDCA and Sherman Law require companies wishing to sell
9 a “drug,” defined as an article “intended for use in the diagnosis, cure, mitigation, treatment, or
10 prevention of disease in man or other animal,” to prove to the FDA that it is safe and effective prior to
11 marketing it. 21 U.S.C. § 321(g)(1)(B); Sherman Law § 109925(b).

12 14. To be proven safe and effective as a new drug, drug companies must first test it and
13 send FDA’s Center for Drug Evaluation and Research (“CDER”) the evidence from these tests to
14 prove the drug is safe and effective for its intended use. A team of CDER physicians, statisticians,
15 chemists, pharmacologist, and other scientists review the company’s data and proposed labeling to
16 determine whether the drug’s health benefits outweigh its known risks.²

17 15. It is a violation of federal and California law to sell a new drug without prior approval
18 by FDA. 21 U.S.C. § 355(a); Sherman Law § 111550.

19 16. A dietary supplement, unlike a drug, is a food intended to supplement the diet that bears
20 or contains a dietary ingredient such as a vitamin, mineral, herb or other botanical, or amino acid. 21
21 U.S.C. § 321(ff).

22 17. Foods, including dietary supplements, are misbranded if they characterize the
23 relationship of a nutrient to a disease or health-related condition unless made in accordance with the
24 FDCA. 21 U.S.C. § 343(r)(1); Sherman Law § 110670.

25
26
27 ² See FDA “How Drugs are Developed and Approved” available online at
28 <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/default.htm>.

1 18. A statement characterizing the relationship of a nutrient to a disease or health-related
2 condition on a dietary supplement may be made only if, “the statement claims a benefit related to a
3 classical nutrient deficiency disease and discloses the prevalence of such disease in the United States,
4 describes the role of a nutrient or dietary ingredient intended to affect the structure or function in
5 humans, characterizes the documented mechanism by which a nutrient or dietary ingredient acts to
6 maintain such structure or function, or describes general well-being from consumption of a nutrient or
7 dietary ingredient.” 21 U.S.C. § 343(r)(6)(A).

8 19. A description of the role of a nutrient or dietary ingredient intended to affect the
9 structure or function in humans is commonly referred to as “structure/function” claims. A
10 structure/function claim may only be made if “the manufacturer of the dietary supplement has
11 substantiation that such statement is truthful and not misleading.” *Id.* § 343(r)(6)(B).

12 20. Importantly, a dietary supplement may not explicitly or implicitly claim to diagnose,
13 cure, mitigate, treat, or prevent a specific disease or class of diseases. 21 U.S.C. § 343(r)(6)(C). For
14 purposes of this law, a “disease” is damage to an organ, part, structure, or system of the body such that
15 it does not function properly (*e.g.*, cardiovascular disease), or a state of health leading to such
16 dysfunctioning (*e.g.*, hypertension); except that diseases resulting from essential nutrient deficiencies
17 (*e.g.*, scurvy, pellagra) are not included in this definition. 21 C.F.R. 101.93(g).

18 21. Pursuant to 21 C.F.R. § 101.93(g)(2), a statement on a dietary supplement claims to
19 diagnose, cure, mitigate, treat, or prevent disease if it claims, explicitly or implicitly, that the product:

- 20 (i) Has an effect on a specific disease or class of diseases;
- 21 (ii) Has an effect on the characteristic signs or symptoms of a specific disease or class of
- 22 diseases, using scientific or lay terminology;
- 23 (iii) Has an effect on an abnormal condition associated with a natural state or process, if
- 24 the abnormal condition is uncommon or can cause significant or permanent harm;
- 25 (iv) Has an effect on a disease or diseases through one or more of the following factors:
 - 26 (A) The name of the product;
 - 27 (B) A statement about the formulation of the product, including a claim that the product
 - 28 contains an ingredient (other than an ingredient that is an article included in the

1 definition of "dietary supplement" under 21 U.S.C. 321(ff)(3)) that has been regulated
2 by FDA as a drug and is well known to consumers for its use or claimed use in
3 preventing or treating a disease;

4 (C) Citation of a publication or reference, if the citation refers to a disease use, and if,
5 in the context of the labeling as a whole, the citation implies treatment or prevention of
6 a disease, e.g., through placement on the immediate product label or packaging,
7 inappropriate prominence, or lack of relationship to the product's express claims;

8 (D) Use of the term "disease" or "diseased," except in general statements about disease
9 prevention that do not refer explicitly or implicitly to a specific disease or class of
10 diseases or to a specific product or ingredient; or

11 (E) Use of pictures, vignettes, symbols, or other means;

12 (v) Belongs to a class of products that is intended to diagnose, mitigate, treat, cure, or
13 prevent a disease;

14 (vi) Is a substitute for a product that is a therapy for a disease;

15 (vii) Augments a particular therapy or drug action that is intended to diagnose, mitigate,
16 treat, cure, or prevent a disease or class of diseases;

17 (viii) Has a role in the body's response to a disease or to a vector of disease;

18 (ix) Treats, prevents, or mitigates adverse events associated with a therapy for a disease, if
19 the adverse events constitute diseases; or

20 (x) Otherwise suggests an effect on a disease or diseases.

21 22. Claims that a product can cure, mitigate, treat, or prevent a disease require prior
22 approval by the FDA and may be made only for products that are approved drug products, or for foods
23 with FDA-approved "health claims." 21 U.S.C. § 355(a) (drugs); 21 C.F.R. 101.93 (f) (food). Failure
24 to obtain prior FDA approval of such a claim in either case renders the claim illegal in violation of 21
25 C.F.R. 101.93 (f) if a food, or 21 U.S.C. § 355(a) if a drug.

26 23. The promotion, advertisement, distribution or sale of substances represented as being
27 effective to diagnose, cure, mitigate, treat, or prevent disease (or other conditions), or provide a
28 beneficial effect on health, but which have not been scientifically proven to and approved by the FDA

1 as safe and effective for such purposes, is called "Health Fraud." FDA Compliance Policy Guide
2 120.500 Health Fraud.³

3 24. FDA classifies Health Fraud as a "major economic cheat" even when a person's health
4 is not directly at risk. *Id.*

5 25. Even if a Health Fraud does not pose a direct risk to a person's health, it can be an
6 indirect health risk when a person relies on a Health Fraud in delaying or discontinuing appropriate
7 medical treatment. *Id.*

8 **GNC'S HEALTH FRAUD**

9 26. GNC sells several products which explicitly or impliedly claim to treat, cure, prevent
10 or mitigate hypercholesterolemia, coronary heart disease and/or osteoporosis without being approved
11 by FDA as being safe or effective for these purposes. Although the products are labeled to treat, cure,
12 prevent or mitigate these diseases or conditions, the products have not been scientifically proven to
13 and approved by the FDA as safe or effective at mitigating, treating, curing or preventing any disease
14 or condition. Accordingly, GNC's products described below are Health Frauds.

15 **Products Claimed to Cure, Mitigate, Treat or Prevent** 16 **Hypercholesterolemia and Coronary Heart Disease**


17 27. Hypercholesterolemia is a condition characterized by high levels of cholesterol in the
18 blood. While the body needs cholesterol to build cell membranes and make certain hormones, too
19 much cholesterol increases a person's risk of developing heart disease and stroke.⁴

20 28. People with hypercholesterolemia, *i.e.*, high cholesterol levels, have a high risk of
21 developing coronary artery disease. This occurs when excess cholesterol in the bloodstream is
22 deposited in the walls of blood vessels, particularly in the arteries that supply blood to the heart
23 (coronary arteries). *See* picture below from the U.S. National Institutes of Health. The abnormal
24 cholesterol buildup forms clumps called plaque that narrow and harden artery walls. As the plaque
25

26 ³ Available online at [https://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidance](https://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidanceManual/ucm073838.htm)
27 [Manual/ucm073838.htm](https://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidanceManual/ucm073838.htm).

28 ⁴ *See* <https://www.nhlbi.nih.gov/health-topics/high-blood-cholesterol>.

1 gets bigger, it can clog the arteries and restrict the flow of blood to the heart. If too much cholesterol
2 builds up, the blood cannot flow through to the heart which can cause a heart attack.



12 29. Due to the seriousness consequences of hypercholesterolemia, and the many health and
13 concomitant medication considerations that go into its treatment, hypercholesterolemia is not
14 amenable to self-diagnosis and treatment, meaning adequate directions for use cannot be written so
15 that a layperson can use a product intended to treat hypercholesterolemia safely.⁵ FDA has not
16 approved over-the-counter medicines to treat hypercholesterolemia, and instructs consumers to
17 consult their physicians about medicines to help treat the condition.⁶ GNC's products described herein
18 have not been approved by FDA as safe and effective for treatment of hypercholesterolemia. Any
19 claim that a dietary supplement can treat, cure, prevent or mitigate hypercholesterolemia or coronary
20 heart disease is a drug claim, and a Health Fraud as it has not been approved by FDA.

21 30. After the passage of the Dietary Supplement Health and Education Act of 1994
22 ("DSHEA"), which established regulatory requirements and procedures for structure/function claims,
23 FDA took public comments and issued regulations to help delineate what would be lawful
24 structure/function claims, and unlawful drug claims. See Final Rule on the Regulations on Statements

25 ⁵ See, e.g., FDA Warning Letter to Multimunity, Inc. dated September 25, 2014 available online at
26 <https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2014/ucm417431.htm>.

27 ⁶ See FDA, High Cholesterol -- Medicines To Help You available online at
28 <https://www.fda.gov/ForConsumers/ByAudience/ucm118595.htm>.

1 Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of
2 the Body, 65 Fed. Reg. 1000-01 (Jan. 6, 2000) (to be codified at 21 C.F.R. Part 101) (hereinafter,
3 "Final Rule"). This included claims on dietary supplement regarding cholesterol levels. *Id.* at 1015-
4 19.

5 31. FDA has long acknowledged that many people think of cholesterol solely in terms of
6 the negative role of high cholesterol and heart disease. Information readily available to consumers on
7 the internet advises of the link between high cholesterol and coronary heart disease.⁷

8 32. Due to consumer perception linking high cholesterol with heart disease, the availability
9 of information discussing the association between high cholesterol levels and coronary heart disease,
10 the serious health consequences resulting from hypercholesterolemia, and the need for professional
11 advice to treat hypercholesterolemia, FDA undertook careful consideration and deliberation in
12 determining what might be considered an acceptable structure/function claim for cholesterol levels
13 made in the labeling of dietary supplements, and what would be considered an unlawful disease claim
14 prohibited by 21 C.F.R. § 101.93. *See* Final Rule at 1015-18.

15 33. FDA acknowledged that references in dietary supplement labeling to physiologic
16 markers or symptoms of a disease that are quantifiably linked to that disease in an official government
17 health agency summary statement or consensus report, such as high cholesterol and coronary heart
18 disease, would be appropriately treated as implied disease claims. Final Rule at 1018. FDA
19 specifically noted that hypercholesterolemia is not just a physiologic marker for coronary heart
20 disease, but is a disease condition itself. *Id.*

21 34. Thus, any claim that a dietary supplement can lower cholesterol, explicit or implicit, is
22 an unlawful drug claim and not a permissible structure/function claim. Final Rule at 1019. FDA
23 determined this despite the then U.S. Surgeon General advocating for the ability of dietary
24 supplements to be marketed for lowering cholesterol due to the prevalence of heart disease. *Id.* FDA

25 ⁷ *See, e.g.,* "What causes high cholesterol?" available at
26 <https://www.medicalnewstoday.com/articles/9152.php>; "High cholesterol" available at
27 <https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/symptoms-causes/syc-20350800>; and "High Cholesterol Risk Factors: available at [https://www.webmd.com/cholesterol-](https://www.webmd.com/cholesterol-management/high-cholesterol-risk-factors)
28 [management/high-cholesterol-risk-factors](https://www.webmd.com/cholesterol-management/high-cholesterol-risk-factors).

1 concluded that claiming a dietary supplement can lower cholesterol is prohibited because the use of
2 ineffective therapies in persons with elevated cholesterol, which can delay or prevent effective
3 treatment, itself poses significant public health risks. *Id.*

4 35. Even though an explicit or implicit claim that a dietary supplement can lower
5 cholesterol is an unlawful disease claim because elevated cholesterol level is a sign of
6 hypercholesterolemia and an important risk factor for heart disease, having cholesterol within the
7 normal range is not a sign or risk factor of disease.

8 36. Due to the tension between consumer understanding of the link between high
9 cholesterol levels and heart disease, and the recognition that normal cholesterol levels are important,
10 to ensure that a dietary supplement's label does not misleadingly imply the ability to cure, mitigate,
11 treat or prevent high cholesterol, FDA determined that claims linking a substance and cholesterol level
12 must make clear that it can only support or maintain cholesterol levels for people whose cholesterol
13 levels are already in a normal range. Final Rule at 1018-19.

14 37. FDA also considered whether maintaining "healthy cholesterol" levels would be an
15 acceptable structure/function claim. Final Rule at 1015. Many consumers understand there is a
16 difference between high-density lipoprotein, often called the "good cholesterol" and low-density
17 lipoprotein, often called "bad cholesterol."⁸ Given this understanding, FDA determined that
18 references to "healthy cholesterol" could be misleading as this term often refers to high density
19 lipoproteins which are believed to be beneficial. *Id.* at 1019.

20 38. FDA thus rejected comments suggesting that a dietary supplement labeled as
21 supporting "normal" or "healthy" cholesterol levels does not imply treatment for hypercholesterolemia
22 and coronary heart disease, because it implies lowering "bad cholesterol," or helping with "good
23 cholesterol." Final Rule at 1018-19. The example FDA gave of an acceptable structure function claim
24 for cholesterol that would not misleadingly suggest lowering "bad" cholesterol, or raising "good"
25 cholesterol is, "helps to maintain cholesterol levels that are already within the normal range." *Id.* at
26 1019.


27 _____
28 ⁸ See https://www.cdc.gov/cholesterol/ldl_hdl.htm.




39. Despite FDA's clear guidance that any claim on a dietary supplement about cholesterol level must make it clear that it can only help maintain or support cholesterol levels that are already within the normal range so that it is not implying that it can help cure, treat, prevent or mitigate hypercholesterolemia and/or coronary heart disease, GNC sells several dietary supplements implying that they can help lower "bad" cholesterol levels, or raise "good" cholesterol levels, because they state they can support healthy or normal cholesterol levels as shown and described below.


40. GNC Healthy Cholesterol Formula (Exhibit 1), Policosanol (Exhibit 2), Ultra Probiotic Complex with Cholesterol Support (Exhibit 3), Probiotic Solutions Adults 50 Plus (Exhibit 4), Women's Ultra Mega 50 Plus Vitapak (Exhibit 5), and GNC's Women's Ultra Mega Menopause Vitapak (Exhibit 6) each implicitly claim to cure, mitigate, treat, or prevent hypercholesterolemia.



41. As shown above, GNC's "Healthy Cholesterol Formula" is labeled as being a "PHYSICIAN FORMULATED NUTRITION SOLUTION[]" that "[s]upports normal, healthy cholesterol & triglyceride levels with clinically studied black tea extracts." Exhibit 1. The product's name itself, "Healthy Cholesterol Formula," has been found misleading by FDA as referring to high density lipoproteins, or "good cholesterol." See Final Rule at 1018-19. Moreover, GNC's Healthy Cholesterol Formula does not state that it will only support cholesterol levels for people whose cholesterol levels are already in a normal range.





WOMEN'S ULTRA MEGA[®] 50 Plus

Dietary Supplement

CLINICALLY STUDIED MULTIVITAMIN

- Antioxidants • Healthy Support
- Heart Health • Bone Health

©2006 GNC. GNC and the GNC logo are registered trademarks of GNC. All other trademarks are the property of their respective owners.

WOMEN'S ULTRA MEGA[®] 50 Plus

At 50 and beyond, your body needs the good stuff that's been proven to help you live longer, feel better, and look your best. That's why 50+ women's health experts recommend Ultra Mega 50 Plus as the most powerful, clinically studied multivitamin—and one woman's secret to staying healthy.

- Women's Health**
 "Ultra Mega 50 Plus is the most powerful multivitamin formula shown to work better than a basic multivitamin."
- Antioxidants**
 "Ultra Mega 50 Plus contains 14 antioxidants that help protect your cells from oxidative stress and improve the body's natural defenses."
- Memory Support**
 "Ultra Mega 50 Plus contains ingredients that help improve memory and cognitive function."
- Heart Health**
 "Ultra Mega 50 Plus contains ingredients that help improve heart health and reduce the risk of heart disease."
- Bone Health**
 "Ultra Mega 50 Plus contains ingredients that help improve bone density and reduce the risk of osteoporosis."

©2006 GNC. GNC and the GNC logo are registered trademarks of GNC. All other trademarks are the property of their respective owners.

45. As shown above, GNC's Women's Ultra Mega 50 Plus Vitapak product is labeled as "containing over 30 clinically studied ingredients" for, amongst other things, "Heart Health." Exhibit 5. The product is also labeled that it, "[h]as EPA, which is important for cardiovascular and circulatory health and promotes healthy cholesterol and triglyceride levels." Exhibit 5. GNC's Women's Ultra Mega 50 Plus Vitapak does not state that it will only support cholesterol levels for people whose cholesterol levels are already in a normal range.

GNC

WOMEN'S ULTRA MEGA[®] Menopause

Dietary Supplement

VITAPAK[®] PROGRAM

- Clinically studied in combination with 2 Plus 1[®] Choline Oil
- Proven to help support heart and cholesterol health with omega-3s
- Supports heart and cholesterol health with omega-3s
- Helps to help support heart and cholesterol health with omega-3s



© 2004 GNC

GNC

WOMEN'S ULTRA MEGA[®] Menopause

Our Women's Ultra Mega[®] Menopause Vitapak[®] Program is a powerful combination of the most potent ingredients to support heart and cholesterol health with omega-3s.

- **Women's Ultra Mega[®] Vitapak[®] Program**
This powerful combination of ingredients is designed to support heart and cholesterol health with omega-3s. It includes the most potent ingredients to support heart and cholesterol health with omega-3s.
- **Menopause Formula**
This powerful combination of ingredients is designed to support heart and cholesterol health with omega-3s. It includes the most potent ingredients to support heart and cholesterol health with omega-3s.
- **Choline Oil**
This powerful combination of ingredients is designed to support heart and cholesterol health with omega-3s. It includes the most potent ingredients to support heart and cholesterol health with omega-3s.

© 2004 GNC

46. As shown above, GNC's Women's Ultra Mega Menopause Vitapak product is labeled as being able to "support a women's overall health," including "heart and cholesterol health with omega-3s." Exhibit 6. GNC's Women's Ultra Mega Menopause Vitapak product does not state that it will only support cholesterol levels for people whose cholesterol levels are already in a normal range.

47. The labeling of GNC's Healthy Cholesterol Formula, Policosanol, Ultra 35 Probiotic Complex with Cholesterol Support, Probiotic Solutions Adult 50 Plus, GNC's Women's Ultra Mega 50 Plus Vitapak and Women's Ultra Mega Menopause Vitapak as being able to maintain and/or support normal or healthy cholesterol levels, without also stating that they will only maintain and/or support cholesterol levels for people whose cholesterol levels are already in a normal range, implies that the products will help cure, mitigate, treat or prevent hypercholesterolemia and/or coronary heart disease by helping lower bad cholesterol.

48. GNC's Healthy Cholesterol Formula, Policosanol, Ultra 35 Probiotic Complex with Cholesterol Support, Probiotic Solutions Adult 50 Plus, GNC's Women's Ultra Mega 50 Plus Vitapak or Women's Ultra Mega Menopause Vitapak products have not been approved by FDA to cure, mitigate, treat or prevent hypercholesterolemia or coronary heart disease.

49. FDA has issued warning letters to companies selling dietary supplements claiming to maintain cholesterol levels without explaining that they will only maintain cholesterol when it is already within a normal range because their labeling indicated they are intended for use in the cure, mitigation, treatment, or prevention of disease. See, e.g., FDA Warning Letter to Nature's Health

1 Company, LLC dated June 30, 2017⁹; FDA Warning Letter to Orgen Nutraceuticals, Inc. dated
2 October 28, 2015.¹⁰

3 50. FDA issues warning letters such as these “only for violations of regulatory
4 significance.”¹¹ FDA warning letters are intended “to correct violations of the statutes or regulations”
5 and “communicate[] the agency’s position on a matter.” *Id.* at 4-2 to 4-3.

6 **Products Claimed to Cure, Mitigate, Treat or Prevent Osteoporosis**

7 51. Osteoporosis, or porous bone, is a disease characterized by low bone mass and
8 structural deterioration of bone, leading to fragility and increased risk of fractures.¹²

9 52. Certain risk factors are linked to the development of osteoporosis and contribute to the
10 likelihood of developing the disease, including abnormal absence of menstrual periods and low
11 estrogen levels caused by menopause.¹³ While menopause is a normal part of aging and not a disease,
12 one of the changes in a woman’s body experiencing menopause is bones become less dense and more
13 vulnerable to fracture.¹⁴ Due to the decrease in bone density, post-menopausal women are more
14 vulnerable to osteoporosis.¹⁵

15
16
17
18 ⁹ Available online at
19 <https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm566680.htm>.

20 ¹⁰ Available online at
21 <https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2015/ucm471279.htm>.

22 ¹¹ FDA, Regulatory Procedures Manual at p. 4-2 (Mar. 2017), available at
23 <http://www.fda.gov/downloads/ICECI/ComplianceManuals/RegulatoryProceduresManual/UCM074330.pdf>.

24 ¹² <https://www.bones.nih.gov/health-info/bone/osteoporosis/overview>.

25 ¹³ *Id.*

26 ¹⁴ See NIH “What Is Menopause?” available online at <https://www.nia.nih.gov/health/what-menopause>.

27 ¹⁵ *Id.*

53. Menopause happens when a woman's ovaries stop making estrogen.¹⁶ The average age a woman enters menopause is 51 years, but it can happen sooner naturally and will happen if a woman has her ovaries removed.¹⁷

54. Estrogen normally acts in the body to help inhibit bone resorption (breakdown).¹⁸ Having low amounts of estrogen being produced by the body, or no estrogen, will cause bone breakdown.¹⁹

55. There is no cure for osteoporosis, but there are a large number of prescription medications and therapy options depending on the patient's health, comorbid diseases and other medications.²⁰ Given the serious consequences of osteoporosis, and the complexity of treatment options, osteoporosis is a disease that is not amenable to self-diagnosis or self-treatment.

56. In implementing the regulations governing structure/function claims on dietary supplements, FDA commented on the labeling of dietary supplements with claims about supporting bones and/or bone fragility. Final Rule at 1013, 17-18. FDA concluded that while a claim that a nutrient can help build or maintain strong bones, without more, is a permitted structure function claim, when associated with osteoporosis or another condition the same claim is an unlawful disease claim because it implies treatment for osteoporosis. *Id.* at 1008.

57. Given the association between menopause and osteoporosis, FDA concluded that a claim that a dietary supplement can maintain, build, strengthen or support bone health and/or bone

¹⁶ See "Hormones and Healthy Bones" from the National Osteoporosis Foundation, available online at <https://cdn.nof.org/wp-content/uploads/2016/02/Hormones-and-Healthy-Bones-1.pdf> at 6.

¹⁷ *Id.* at 6; See WebMD "Your Guide to Menopause" available online at <https://www.webmd.com/menopause/guide/menopause-information#1> (menopause starts around age 51 and completed within 4 years).

¹⁸ For review, see Siddiqui, Jawed A. and Nicola C. Partridge. Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement. *Physiology* (Bethesda). 2016 May;31(3):233-45 available online at <https://www.physiology.org/doi/full/10.1152/physiol.00061.2014>.

¹⁹ *Id.*

²⁰ See, e.g., <https://www.fda.gov/forconsumers/byaudience/forwomen/ucm118551.htm>; <https://americanbonehealth.org/fda-approved-treatments/>; and Tu, Kristi N. et al. Osteoporosis: A Review of Treatment Options. *Pharmacy and Therapeutics*. 2018 Feb; 43(2): 92-104.

1 density combined with an express or implied claim about menopause -- including targeting the
2 advertising towards post-menopausal women -- expressly or impliedly claims that the product can help
3 cure, mitigate, treat or prevent osteoporosis. See Final Rule at 1013 (indicating a statement that a
4 dietary supplement can prevent bone fragility in post-menopausal women is a disease treatment or
5 prevention claim); *id.* at 1014 (indicating the required disclaimer that a claim on a dietary supplement
6 had not been reviewed or approved by FDA was insufficient to make a claim about preventing bone
7 fractures in post-menopausal women due to bone loss into a lawful claim); *id.* at 1017 (claiming that
8 product prevents bone fragility in post-menopausal women clearly implies that the product prevents
9 osteoporosis); *id.* at 1018 (claiming that a dietary supplement will maintain normal bone density in
10 post-menopausal women is a disease claim because post-menopausal women characteristically
11 develop osteoporosis, a disease whose principal sign is decreased bone mass). Thus, the labeling of a
12 dietary supplement as being able to maintain, build, strengthen or support bones in menopausal women
13 is an unlawful disease claim.


14 58. Despite FDA's clear guidance that a dietary supplement cannot be labeled as being able
15 to maintain, build, strengthen or support bone health in menopausal women, GNC's Women's Ultra
16 Mega 50 Plus, Women's Ultra Mega 50 Plus Vitapak and Women's Ultra Mega Menopause Vitapak
17 products explicitly or implicitly claim to cure, mitigate, treat or prevent osteoporosis for menopausal
18 women.

19 59. GNC's Women's Ultra Mega 50 Plus Vitapak, pictured on Page 15 *supra*, by its very
20 name is targeted towards women 50 years and older who are typically menopausal. Exhibit 5.

21 60. GNC's Women's Ultra Mega 50 Plus Vitapak is labeled as being a "CLINICALLY
22 STUDIED MULTIVITAMIN" for, among other things, "Bone Health." Exhibit 5. GNC's Women's
23 Ultra Mega 50 Plus Vitapak is also labeled to "[f]eature[] MBP[®], which is clinically studied to support
24 the body's natural ability to build and maintain healthy bones." Exhibit 5. As GNC's Women's Ultra
25 Mega 50 Plus Vitapak is targeted towards menopausal women and is labeled to build, support and
26 maintain bones, it is unlawfully labeled to cure, treat, prevent or mitigate osteoporosis.

61. GNC's Women's Ultra Mega Menopause Vitapak, pictured on page 16 *supra*, is by its very name explicitly marketed towards menopausal women. Exhibit 6. The back of the product states it includes a "Menopause formula" with ingredients that "act as mild estrogens..."

62. GNC's Women's Ultra Mega Menopause Vitapak is also labeled as being able to "[h]elp[] build and maintain bone density with 1,000 mg calcium." The back of GNC's Women's Ultra Mega Menopause Vitapak states it contains a combination of "clinically studied ... vitamins and minerals designed specifically to emphasize the key nutrients for bone health." Exhibit 6. GNC's Women's Ultra Mega Menopause Vitapak is also labeled as being "shown to support natural bone building," and as containing ingredients "which are essential nutrients involved in the formation of the bone matrix." Exhibit 6. As GNC's Women's Ultra Mega Menopause Vitapak is marketed for menopausal women and is labeled to build, support and/or maintain bone density, it is unlawfully labeled to cure, treat, prevent or mitigate osteoporosis.



63. GNC's Women's Ultra Mega 50 Plus, pictured above, is by its very name targeted towards women 50 years and older who are typically menopausal. Exhibit 7.

64. GNC's Women's Ultra Mega 50 Plus is labeled as being a "CLINICALLY STUDIED MULTIVITAMIN" for, among other things, "Bone Health." Exhibit 7. GNC's Women's Ultra Mega 50 Plus is also labeled as being able to "Strengthen[] bones with calcium and vitamin D-3," and as containing "a potent calcium and vitamin D complex to support strong bones." Exhibit 7. As GNC's

1 Women's Ultra Mega 50 Plus is targeted towards menopausal women and is labeled to strengthen and
2 support bones, it is unlawfully labeled to cure, treat, prevent or mitigate osteoporosis.

3 65. The labeling of GNC's Women's Ultra Mega 50 Plus Vitapak, Women's Ultra Mega
4 Menopause Vitapak, and Women's Ultra Mega 50 Plus as being able to build, support, and/or maintain
5 bones implies that the products will help cure, mitigate, treat or prevent osteoporosis because the
6 products are targeted towards menopausal women who typically experience osteoporosis.

7 66. None of GNC's Women's Ultra Mega 50 Plus, Women's Ultra Mega Menopause
8 Vitapak or Women's Ultra Mega 50 Plus Vitapak products have been approved by FDA for the
9 treatment, prevention, cure or mitigation of osteoporosis.

10 **Labeling Products with Drug or Disease Claims without FDA Approval is Misleading**

11 67. The labeling of products that claim to cure, treat, prevent or mitigate diseases or other
12 health related conditions, when they have not been approved as being safe and effective to do so, is
13 misleading. See FDA Health Fraud Scams²¹.

14 68. To the extent GNC's supplements cannot cure, treat, prevent or mitigate the diseases
15 or conditions for which they imply treatment, the labeling of the supplements is false and misleading.

16 69. Even if GNC's supplements are not completely ineffective for the advertised benefits,
17 the labeling of GNC's products as dietary supplements, and not as over-the-counter ("OTC") or
18 prescription drugs, is still misleading as the labeling omits information that is material to consumers.

19 70. Congress charged FDA with ensuring that all drugs (*i.e.*, prescription and OTC) are not
20 only safe and effective, but that their labeling adequately informs users of the risks and benefits of the
21 product, and that its labeling is truthful and not misleading.

22 71. FDA makes its determination on all drug approval (*i.e.*, prescription and OTC) based
23 on a comprehensive scientific evaluation of a product's risks and benefits under the conditions of use
24 prescribed, recommended, or suggested in the labeling. 21 U.S.C. § 355(d).

25 72. FDA considers not only complex clinical issues related to the use of the product in
26 study populations, but also important and practical public health issues pertaining to the use of the

27 _____
28 ²¹ Available online at <https://www.fda.gov/ForConsumers/ProtectYourself/HealthFraud/default.htm>.

1 product in day-to-day clinical practice, such as the nature of the disease or condition for which the
2 product will be indicated, and the need for risk management measures to help assure in clinical practice
3 that the product maintains its favorable benefit-risk balance. 71 Fed. Reg. 3922, 3934 (January 24,
4 2006).

5 **Prescription Drug Labeling**

6 73. For prescription drugs, the centerpiece of risk management generally is the labeling
7 which reflects thorough FDA review of the pertinent scientific evidence and communicates to health
8 care practitioners the agency's formal, authoritative conclusions regarding the conditions under which
9 the product can be used safely and effectively. FDA carefully controls the content of labeling for a
10 prescription drug, because such labeling is FDA's principal tool for educating health care professionals
11 about the risks and benefits of the approved product to help ensure safe and effective use. FDA
12 continuously works to evaluate the latest available scientific information to monitor the safety of
13 products and to incorporate information into the product's labeling when appropriate. 71 Fed. Reg. at
14 3934

15 74. Labeling, as defined by the FDCA, "means all labels and other written, printed, or
16 graphic matter (1) upon any article or any of its containers or wrappers, or (2) accompanying such
17 article." 21 U.S.C. § 321(m).

18 75. The requirements for prescription drug labeling are set forth in 21 C.F.R. § 201.56.
19 Amongst other things, prescription drug labeling must include:

- 20 a. A summary of the essential scientific information needed for the safe and
21 effective use of the drug;
 - 22 b. the information must be informative and accurate
 - 23 c. the information may not be promotional in tone, and nothing false or misleading
24 may be included;
 - 25 d. no implied claims or suggestions for use if evidence of safety or efficacy is
26 lacking; and
 - 27 e. based, whenever possible, on human testing.
- 28

1 76. The FDA approves prescription drug labels based on its analysis of a new drug
2 application or biologics license application, and contains information "necessary for safe and effective
3 use." 71 Fed. Reg 3911-01, 3922 (January 24, 2006).

4 77. The primary purpose of prescription drug labeling is to give healthcare practitioners
5 the information they need to prescribe drugs appropriately. *Id.* at 3961. The information in
6 prescription drug labeling, and the format it is presented, is to give healthcare professionals the ability
7 to access, read and use drug information. *Id.* at 3923.

8 78. Amongst other things, prescription drug labeling must include: Highlights of
9 prescribing information that includes the dosage; concise summary of any boxed warnings; indications
10 and usage; dosage and administration; dosage forms and strengths; contraindications; warnings and
11 precautions; and adverse reactions. 21 C.F.R. § 201.57(a).

12 79. Prescription drug labeling must also include Full Prescribing information with
13 appropriate headings and subheadings that detail any boxed warnings; indications and usage; dosage
14 and administration; dosage forms and strengths; contraindications; warnings and precautions; adverse
15 reactions; drug interactions; use in specific populations, pregnancy risks; effects on reproductive
16 potential; pediatric use; geriatric use; description including chemical and physical information; clinical
17 pharmacology; nonclinical toxicology; clinical studies; references; proper storage and handling;
18 patient counseling information. 21 C.F.R. § 201.57(b)-(c).

19 80. The information must be presented in a uniform way, with a specific format and with
20 minimal type size requirements to make reading and understanding the information easy. 21 C.F.R. §
21 201.57(d).

22 81. The ultimate purpose of prescription drug labeling is to give healthcare practitioners
23 the information they need, in a uniform and easily-readable format, to keep consumers from harm
24 through the use of appropriate drugs. Consumers rely on their health care practitioners to have all of
25 the critical information about a drug when recommending it for a specific purpose. Thus, the failure
26 to label prescription drugs accurately, with all of the required information and in the required format,
27 is material to consumers and it can lead to harm through the misuse of such drugs.

1 85. "Active Ingredients" must have an established name, and list the quantity or proportion
2 of each active ingredient immediately below a prominent title to enable consumers to quickly and
3 systematically compare ingredient within products for similar uses. 64 Fed. Reg. 13254-01, 13260.

4 86. "Purpose" is the FDA-approved description of the principal intended action of the drug
5 or each active ingredient. 21 C.F.R. § 201.66(c)(3).

6 87. "Uses" provides the indications for use of the product. 21 C.F.R. § 201.66(c)(4).

7 88. "Warnings" provides specific information and subheadings including whether the
8 product is for external use only and, as appropriate, for rectal or vaginal use; Reye's syndrome warning
9 if the product contains salicylates; allergic reaction and asthma alert warnings; contraindications when
10 consumers should not use the product unless a doctor directs the usage; preexisting conditions
11 warnings; juvenile warnings; pregnancy warnings; accidental ingestion/overdose warning. 21 C.F.R.
12 § 201.66(c)(5).

13 89. Directions for use, such as specific age categories, how much to take, how to take, and
14 how often and how long to take. 21 C.F.R. § 201.66(c)(6).

15 90. Other Information required by the FDA specifically excluding any promotional
16 material as it is generally not necessary for the safe and effective use of the product. 21 C.F.R. §
17 201.66(c)(7) and 64 Fed. Reg. 13254-01, 13263.

18 91. Inactive Ingredients are to be listed in accordance with 21 C.F.R. § 201.66(c)(8).

19 92. Questions or Comments that provides a telephone number for a source to answer
20 questions about the product. 21 C.F.R. § 201.66(c)(9).

21 93. Having all of the required information, and have it presented in a uniform way, is
22 material to consumers who wish to make an educated decision about what drugs they are putting into
23 their bodies, as well as whether it is the best and/or most economical product for what they are trying
24 to accomplish. The failure to include any of this information on an OTC drug product is not only
25 unlawful, but it prevents consumers from being able to comparative shop for the most appropriate
26 product for their needs.

27 94. Unless FDA has given a specific exemption from including required information on an
28 OTC drug's label, its inclusion is material to consumers. The omission of any information from the

1 labeling of a food or drug that is material in light of the claims made for the product or the
2 consequences that may result from using the product deems the product misleading and misbranded.
3 21 C.F.R. § 1.21(a).

4 **GNC Refused To Cease Its Wrongdoing**

5 95. On November 17, 2017, Mr. Clark and Ms. Labajo, through his counsel and pursuant
6 to California's Consumers Legal Remedies Act ("CLRA"), Cal. Civ. Code § 1782, sent GNC a
7 certified letter notifying GNC of particular violations of Civil Code § 1770, and demanded that GNC
8 correct, repair or otherwise rectify the problems associated with its unlawful behavior which are in
9 violation of Civil Code § 1770 ("CLRA Letter"). A copy of the CLRA Letter is attached hereto as
10 Exhibit 9 (exhibits thereto omitted).²³

11 96. GNC failed to respond to the CLRA Letter.

12 97. To date, the labels of the Products being the unlawful claims detailed herein have not
13 changed, and GNC has yet to respond to the CLRA Letter.

14 98. As GNC has failed to respond to the CLRA Letter, and the Products' labels have not
15 changed, it appears GNC is and continues to be unwilling to change the labeling of the Products to
16 remove the drug claims identified in the CLRA Letter and throughout this Complaint, or to submit a
17 new drug application with FDA in order to have its products approved as new drugs with appropriate
18 drug labeling.

19 99. GNC has not stopped using or corrected, repaired or otherwise rectified the unlawful
20 labeling practices identified in the CLRA Letter and described in this Complaint.

21 **FIRST CAUSE OF ACTION** 22 **("Unlawful" Business Practices in Violation of** 23 **The Unfair Competition Law, Bus. & Prof. Code §§ 17200, et seq.)**

24 100. Plaintiffs hereby incorporate all other paragraphs of this Complaint and restate them as
25 if fully set forth herein.

26 ²³ The CLRA Letter also set forth claims regarding abnormal blood glucose levels, inflammation,
27 oxidative stress, and statin therapy in other of GNC's products. However, Plaintiffs are not asserting
28 any claims regarding abnormal blood glucose levels, inflammation, oxidative stress, and statin therapy
in GNC's products in this Complaint.

1 101. California's Unfair Competition Law ("UCL") defines unfair business competition to
2 include any "unlawful, unfair or fraudulent" act or practice. Cal. Bus. & Prof. Code § 17200.

3 102. A business practice is "unlawful" if it violates any established state or federal law.

4 103. Sherman Law § 111550 prohibits the sale, delivery or gift of any new drug without
5 approval of a new drug application by FDA or California's Department of Health Services.

6 104. Sherman Law § 109925 and FDCA § 201(g)(1) define "drug" as, amongst other things,
7 any article used or intended for use in the diagnosis, cure, mitigation, treatment, or prevention of
8 disease in humans or other animals. Any food for which a health claim has been approved by FDA
9 pursuant to FDCA §§ 403(r)(1)(B) and 403(r)(3) for conventional foods, or §§ 403(r)(1)(B) and
10 403(r)(5)(D) for dietary supplements, is not a drug solely because the label or labeling contains such
11 a claim. Unlike conventional foods, dietary supplements cannot be labeled with health claims based
12 on an authoritative statement of the National Academy of Sciences or a scientific body of the U.S.
13 government with responsibility for public health protection or nutrition research.

14 105. A "new drug" is any drug which has not been proven to be safe and effective for use
15 under conditions prescribed, recommended or suggested in the labeling or advertising thereof. 21
16 C.F.R. § 321(p); Sherman Law 10998.

17 106. As explained above, GNC's Products are new drugs as they are labeled as being
18 intended to cure, treat, mitigate or prevent hypercholesterolemia, coronary heart disease and/or
19 osteoporosis in humans. However, none of GNC's Products identified in this complaint have been
20 approved as a new drug by FDA or California's Department of Health Services for these purposes.

21 107. GNC violated and continues to violate Sherman Law § 111550 through the sale,
22 delivery or gift of each of the new drug products identified herein without approval of a new drug
23 application by FDA or California's Department of Health Services, and hence also violated and
24 continues to violate the "unlawful" prong of the UCL.

25 108. The Sherman Law also prohibits the advertisement of any food or drug that is
26 misbranded. Sherman Law § 110398. Advertisement for the purpose of the Sherman Law includes
27 any representations about a product including statements on the packaging. Sherman Law § 109885.

1 109. Sherman Law § 111440 prohibits the manufacture, sale, delivery, holding or offer to
2 sell a misbranded drug, and § 111445 prohibits the misbranding a drug.

3 110. Food and drugs are misbranded if their labeling is false or misleading in any particular.
4 Sherman Law §§ 110660 and 111330 (respectively).

5 111. The labeling of a food or drug is misleading if it fails to reveal facts that are material
6 in light of other representations made, or if it fails to include affirmative disclosure of material facts
7 required by FDA regulations promulgated pursuant to the FDCA. 21 C.F.R. § 1.21.

8 112. The Sherman Law adopts FDA regulations of food and drugs as the law of California.
9 Sherman Law §§ 110100 (food); 110110 (new drugs) 110111 (OTC drugs).

10 113. GNC's Products labeled as drugs fail to provide material information required by FDA
11 for all drug products as explained above. Due to GNC's omission of this material information, the
12 Products are misbranded and GNC violated, and continues to violate, 21 C.F.R. § 1.21 and Sherman
13 Law §§ 110110 and 110111.

14 114. Moreover, due to the omission of the material drug information which renders the
15 Products misbranded, GNC violated, and continues to violate, Sherman Law §§ 111440, 111445,
16 110660, 111330 by misbranding the Products, manufacturing, selling, delivering and offering to sell
17 misbranded Products.

18 115. GNC's identical conduct that violates the Sherman Law also violates the FDCA, 21
19 U.S.C. §§ 331(a), (b), (d), (g), 352 and 355, and FDA regulations, 21 C.F.R. § 201.57, 21 C.F.R. §
20 201.66. This identical conduct serves as the sole factual basis of each cause of action brought by this
21 Complaint, and Plaintiffs do not seek to enforce any of the state law claims raised herein to impose
22 any standard of conduct that exceeds that which would violate the FDCA and applicable FDA
23 regulations.

24 116. By committing the unlawful acts and practices alleged above, GNC has engaged, and
25 continues to be engaged, in unlawful business practices within the meaning of the UCL.

26 117. As a result of GNC's unlawful conduct, GNC has obtained money from Plaintiffs, and
27 Plaintiffs have suffered injury in fact and lost money or property. As such, Plaintiffs request that this
28

1 Court enjoin GNC from continuing to violate the UCL or violating it in the same fashion in the future
2 as discussed herein pursuant to Cal. Bus. & Prof. Code §17203.

3 **SECOND CAUSE OF ACTION**
4 **(Violation of the Consumers Legal Remedies Act,**
5 **California Civil Code §§ 1750, *et seq.*)**

6 118. Plaintiffs hereby incorporate all other paragraphs of this Complaint and restate them as
7 if fully set forth herein.

8 119. This cause of action is brought pursuant to the CLRA, California Civil Code §§ 1750,
9 *et seq.*

10 120. Plaintiffs are "consumers" within the meaning of Cal. Civ. Code § 1761(d).

11 121. Plaintiffs' purchases of GNC's Products are "transactions" within the meaning of Cal.
12 Civ. Code § 1761(e) and the Products manufactured and sold by GNC are "goods" within the meaning
13 of Cal. Civ. Code § 1761(a).

14 122. By labeling and advertising the Products with disease and drug claims without having
15 been approved as being safe and effective for their labeled purposes, GNC violated and continues to
16 violate the CLRA in at least the following respects:

17 a. in violation of California Civil Code § 1770(a)(5), GNC represented that the Products
18 had characteristics which they did not have;

19 b. in violation of California Civil Code § 1770(a)(7), GNC represented that the Products
20 were of a particular standard, quality or grade, which they were not; and

21 c. in violation of California Civil Code § 1770(a)(9), GNC advertised the Products with
22 the intent not to provide what they advertised.

23 123. GNC knew or should have known that the disease and drug claims, without being
24 approved by FDA or California's Department of Health and without the required drug facts on the
25 labeling of the Products, violated the FDCA, FDA regulations, the Sherman Law and the CLRA, that
26 such claims and omissions were material and that said claims and omissions would be relied upon by
27 consumers including Plaintiffs.

28 124. As described herein, GNC obtained money from Plaintiffs through its unlawful acts
and practices because Plaintiffs purchased GNC's Products identified in ¶¶ 6-8 relying, in part, on the

1 Products' labeling which was material to Plaintiffs' decisions to purchase the products. As a result of
2 GNC's conduct, Plaintiffs have suffered injury in fact and lost money or property.

3 125. Accordingly, pursuant to Cal. Civ. Code § 1780(a)(2), Plaintiffs requests that the Court
4 enjoin GNC from continuing to violate the CLRA by selling or offering for sale the Products in
5 California, or causing the Products to be sold or offered for sale in California.

6 126. With respect to the violations of Civil Code § 1770 as to which GNC was notified of
7 the problems with its Products' labeling, but refused to repair or otherwise rectify the problems with
8 its unlawful acts, Plaintiffs hereby request damages for their purchases of the GNC Products as
9 provided for in Civil Code § 1780, including:

- 10 a. Actual damages;
- 11 b. restitution;
- 12 c. any other relief which the Court deems proper; and
- 13 d. court costs and attorneys' fees.

14 JURY DEMAND

15 Plaintiffs demand a jury trial on all causes of action and/or issues so triable.

16 PRAYER FOR RELIEF

17 WHEREFORE, Plaintiffs prays for relief and judgment against GNC as follows:

18 A. A declaration and Order enjoining GNC from misbranding, manufacturing, selling,
19 delivering, holding or offering for sale, selling or offering for sale, delivering or proffering for delivery
20 the Products labeled with unapproved drug or disease claims in violation of California's Sherman Law
21 and other applicable laws and regulations as specified in this Complaint.


22 B. Compensatory damages or restitution in such amount that Plaintiffs paid to purchase
23 GNC's products for the Second Cause of Action only;

24 C. An Order awarding Plaintiffs their costs of suit, attorneys' fees and pre-and post-
25 judgment interest; and

26 D. Such other and further relief as the Court may deem just and proper.

1 Dated: March 12, 2019

FEINSTEIN DOYLE PAYNE
& KRAVEC, LLC

2
3 By: 
Wyatt A. Lison

4 429 Fourth Avenue, Suite 1300
5 Pittsburgh, PA 15219
6 Telephone: (412) 281-8400
Facsimile: (412) 281-1007

7 John Peter Zavez (pro hac vice to be filed)
8 ADKINS, KELSTON & ZAVEZ, P.C.
9 90 Canal Street, Suite 120
Boston, MA 02114
10 Telephone: (617) 367-1040
Facsimile: (617) 742-8280

11 **ATTORNEYS FOR PLAINTIFFS**